Asamer Eva, Szkandera Joanna, Gibiser Paul, Lembeck Anna Lena, Stojakovic Tatjana, Kornprat Peter, Lackner Caroline, Winder Thomas, Schlick Konstantin, Stöger Herbert, Gerger Armin, Pichler Martin, Stotz Michael
Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Wien Klin Wochenschr. 2018 Oct;130(19-20):569-574. doi: 10.1007/s00508-018-1383-3. Epub 2018 Aug 21.
The aim of this study was to investigate the prognostic relevance of plasma amylase and lipase concerning survival of patients suffering from metastatic pancreatic cancer (PC).
This retrospective study included 351 patients with metastatic PC, who were treated in a single academic institution. Cancer-specific survival (CSS) was analyzed using the Kaplan-Meier method. To further evaluate the prognostic significance of lipase and amylase, univariate and multivariate values were calculated using Cox proportional models.
In univariate analysis, an increased amylase level was associated with shorter CSS in PC patients (hazard ratio HR = 1.258; 95% confidence interval CI = 1.011-1.566; p = 0.039). In multivariate analysis, including gender, age, CA19-9 and administration of chemotherapy, increased amylase levels prevailed as an independent prognostic factor for CSS (HR = 1.373; 95%CI = 1.004-1.878; p = 0.047).
Plasma amylase was found to be an independent prognostic factor in patients with metastatic PC. The results indicate that amylase might represent a novel and useful marker for better patient stratification in PC management.
本研究旨在探讨血浆淀粉酶和脂肪酶与转移性胰腺癌（PC）患者生存的预后相关性。
本回顾性研究纳入了在单一学术机构接受治疗的351例转移性PC患者。采用Kaplan-Meier法分析癌症特异性生存（CSS）情况。为进一步评估脂肪酶和淀粉酶的预后意义，使用Cox比例模型计算单变量和多变量值。
在单变量分析中，淀粉酶水平升高与PC患者较短的CSS相关（风险比HR = 1.258；95%置信区间CI = 1.011 - 1.566；p = 0.039）。在多变量分析中，包括性别、年龄、CA19-9和化疗给药情况，淀粉酶水平升高作为CSS的独立预后因素依然存在（HR = 1.373；95%CI = 1.004 - 1.878；p = 0.047）。
发现血浆淀粉酶是转移性PC患者的独立预后因素。结果表明，淀粉酶可能是PC管理中更好地对患者进行分层的一种新的有用标志物。
